Selio Medical – Medical Device Innovation

Clinical Need

Lung cancer is the most common cancer worldwide & lung biopsy is the gold standard method of diagnosis
Early diagnosis has been proven to save lives making lung biopsy a vital armament in the battle against lung cancer
Unfortunately, 1 in 3 patients undergoing a lung biopsy suffer from a collapsed lung, known as pneumothorax
This dangerous complication converts a routine outpatient procedure to one requiring hospitilisation, for up to a week, for invasive treatment & follow-up
This results in healthcare costs in excess of $15,000 per patient making it the No. 1 hospital cost & complication post lung biopsy

Technology

Selio Medical adopts a unique approach by preventing the pneumothorax occurring before the biopsy even takes place.
The Selio System™ is a single use, prophylactic device, comprising a smart delivery needle together with a biodegradable hydrogel sealant.
Our proven technology seamlessly integrates with the current standard of care and enables the clinician to pre-seal the access route into the lung before the biopsy.
The Selio System™ allows the patient to safely return home on the same day as their procedure. This significantly improves the patient’s quality of care while preventing further treatment and costs.

News

Selio Medical, Headstart/Proof-of-Concept Winner 2017 : EIT Health UK-Ireland @ Oxford University. Read more

Selio Medical, Top 4 Winner at Medtech Innovator Finals San Jose out of over 600 medical device start-up companies. Read more

Selio Medical feature in The Irish Times. Read more

Selio Medical wins Medtech Innovator International Pitch Competition. Read more

Selio Medical highlighted as one of 5 Irish big ideas that can transform medical treatment. Read more

Selio Medical chosen in top 10 of Enterprise Ireland Big Ideas Competition 2017. Read more

Selio Medical selected as first international company to take part in prestigious National Science Foundation icorps accelerator program. Completed in Gerogia Tech, Atlanta 2017. Read more

About

Co-founders Dr Garrett Ryan and Colm McGarvey identified this large unmet clinical need during the Bioinnovate Fellowship Programme. Subsequently, the technology was optimised and de-risked at Trinity College Dublin largely supported by grant funding from Enterprise Ireland. Selio Medical is currently based in Dublin, Ireland.

Dr. Garrett Ryan

An honest and results focused engineer with extensive experience in the development and commercialisation of medical devices. He has led multiple medical devices from concept to market in the cardiovascular, endo-surgery, urological and respiratory fields. Garrett completed both his undergraduate and PhD training at National University of Ireland, Galway.

Colm McGarvey

An ambitious, dynamic and visionary professional with over 22 years commercial experience, national and international, within the medical device and pharmacy sectors. Colm holds a BSc Degree in Pharmacy from Queens University Belfast and a MSc in Bio-Innovation from University College Cork.

Pneumothorax Protection

Developing a Safe, Effective & User Friendly Device to Prevent Pneumothorax During Transthoracic Needle Biopsy

Clinical Need

Lung cancer is the most common cancer worldwide & lung biopsy is the gold standard method of diagnosis

Early diagnosis has been proven to save lives making lung biopsy a vital armament in the battle against lung cancer

Unfortunately, 1 in 3 patients undergoing a lung biopsy suffer from a collapsed lung, known as pneumothorax

This dangerous complication converts a routine outpatient procedure to one requiring hospitilisation, for up to a week, for invasive treatment & follow-up

This results in healthcare costs in excess of $15,000 per patient making it the No. 1 hospital cost & complication post lung biopsy